Mark E. Wood

St. Luke's Campus, 
Exeter, ENG, GB 
Clinical Trials:Currently Recruiting for 2 Trials
St. Luke's Campus, 
Exeter, ENG, GB 

Overview

Mark Wood practices practicing medicine in Exeter, United Kingdom.

His clinical expertise encompasses Ataxia-Telangiectasia, Juvenile Idiopathic Arthritis (JIA), Telangiectasia, and Obstructive Uropathy.

He is actively involved in clinical research, co-authoring 59 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

St. Luke's Campus, Exeter, ENG EX12LU, United Kingdom
Other Locations
Leeds, ENG, United Kingdom
Truro, ENG TR13HD, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3

59 Total Publications

AP39, a novel mitochondria-targeted hydrogen sulfide donor, promotes cutaneous wound healing in an in vivo murine model of acute frostbite injury.
AP39, a novel mitochondria-targeted hydrogen sulfide donor, promotes cutaneous wound healing in an in vivo murine model of acute frostbite injury.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 18, 2024

Frequently Asked Questions about Mark E. Wood

Is Mark E. Wood a top-rated expert for Ataxia-Telangiectasia?

MediFind is an objective health platform that identifies experts based on real-world data. Mark E. Wood is classified as an Experienced expert for Ataxia-Telangiectasia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mark E. Wood participate in research or clinical trials?

Yes. Mark E. Wood has published 59 articles and abstracts on conditions like Ataxia-Telangiectasia. You can view a list of Mark E. Wood's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wood's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile